Northwest Biotherapeutics, Inc. Common stock
NWBO
NWBO was delisted on the 16th of December, 2016.
75 hedge funds and large institutions have $129M invested in Northwest Biotherapeutics, Inc. Common stock in 2015 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 33 increasing their positions, 11 reducing their positions, and 6 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 11
83% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 6
65% more capital invested
Capital invested by funds: $78M → $129M (+$51M)
7% more funds holding
Funds holding: 70 → 75 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
59% less call options, than puts
Call options by funds: $4.47M | Put options by funds: $10.9M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WIM
Woodford Investment Management
London,
United Kingdom
|
+$17.6M |
| 2 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$2.27M |
| 3 |
Goldman Sachs
New York
|
+$1.15M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$970K |
| 5 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$875K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$2.73M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$1.41M |
| 3 |
CA
Commerzbank Aktiengesellschaft
Frankfurt,
Germany
|
-$1.12M |
| 4 |
Morgan Stanley
New York
|
-$516K |
| 5 |
BFIC
Bedell Frazier Investment Counselling
Walnut Creek,
California
|
-$330K |
NWBO Hedge Fund Activity: Q1 2015 in Review
75 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. Common stock (NWBO) for Q1 2015, worth a combined $129M — up 65% from $78M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new NWBO positions and 6 closed out — a net gain of 5 holders — while 33 added to existing stakes and 11 trimmed.
The largest buyer was Woodford Investment Management, adding an estimated $17.6M. The largest seller was Royal Bank of Canada, exiting entirely with an estimated $2.73M sold.
- 75 institutional investors held Northwest Biotherapeutics, Inc. Common stock (NWBO) as of Q1 2015, up from 70 in Q4 2014.
- Funds reported $129M of Northwest Biotherapeutics, Inc. Common stock stock for Q1 2015, up 65% quarter-over-quarter.
- 11 funds opened new Northwest Biotherapeutics, Inc. Common stock positions in Q1 2015 and 6 closed out, a net change of +5 holders.
- The largest Northwest Biotherapeutics, Inc. Common stock buyer in Q1 2015 was Woodford Investment Management, an estimated $17.6M added.
- The largest Northwest Biotherapeutics, Inc. Common stock seller in Q1 2015 was Royal Bank of Canada, an estimated $2.73M sold.
Based on aggregated 13F filings for Q1 2015.